Future perspective: immunomodulatory therapy for autoimmune hepatitis

Marcial Sebode; Ansgar W Lohse

doi:10.1159/000360493

Future perspective: immunomodulatory therapy for autoimmune hepatitis

Standard

Future perspective: immunomodulatory therapy for autoimmune hepatitis. / Sebode, Marcial ; Lohse, Ansgar W.

in: DIGEST DIS, Jahrgang 32, Nr. 5, 01.01.2014, S. 502-506.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Sebode, M & Lohse, AW 2014, 'Future perspective: immunomodulatory therapy for autoimmune hepatitis', DIGEST DIS, Jg. 32, Nr. 5, S. 502-506. https://doi.org/10.1159/000360493

APA

Sebode, M., & Lohse, A. W. (2014). Future perspective: immunomodulatory therapy for autoimmune hepatitis. DIGEST DIS, 32(5), 502-506. https://doi.org/10.1159/000360493

Vancouver

Sebode M , Lohse AW. Future perspective: immunomodulatory therapy for autoimmune hepatitis. DIGEST DIS. 2014 Jan 1;32(5):502-506. https://doi.org/10.1159/000360493

Bibtex

@article{bd8e3d6eff1e4860b6a5247e00487202,

title = "Future perspective: immunomodulatory therapy for autoimmune hepatitis",

abstract = "In the last two decades, more and more light has been shed on the immunologic pathogenesis of autoimmune liver diseases, notably autoimmune hepatitis (AIH). An immunologic dysbalance with proinflammatory immune responses dominating over hepatic tolerance seems to be part of AIH pathogenesis. In detail, an impairment of regulatory T cells (Treg) is suspected. If this holds true and reduced Treg numbers or their function are pathogenic for AIH, this offers the option of cellular or immunomodulatory therapy. However, the exact immunological role of Treg in AIH still needs to be clarified before cellular therapy is promising for patients.",

keywords = "Hepatitis, Autoimmune, Humans, Immunomodulation, Models, Immunological, T-Lymphocytes, Regulatory",

author = "Marcial Sebode and Lohse, {Ansgar W}",

year = "2014",

month = jan,

day = "1",

doi = "10.1159/000360493",

language = "English",

volume = "32",

pages = "502--506",

journal = "DIGEST DIS",

issn = "0257-2753",

publisher = "S. Karger AG",

number = "5",

}

RIS

TY - JOUR

T1 - Future perspective: immunomodulatory therapy for autoimmune hepatitis

AU - Sebode, Marcial

AU - Lohse, Ansgar W

PY - 2014/1/1

Y1 - 2014/1/1

N2 - In the last two decades, more and more light has been shed on the immunologic pathogenesis of autoimmune liver diseases, notably autoimmune hepatitis (AIH). An immunologic dysbalance with proinflammatory immune responses dominating over hepatic tolerance seems to be part of AIH pathogenesis. In detail, an impairment of regulatory T cells (Treg) is suspected. If this holds true and reduced Treg numbers or their function are pathogenic for AIH, this offers the option of cellular or immunomodulatory therapy. However, the exact immunological role of Treg in AIH still needs to be clarified before cellular therapy is promising for patients.

AB - In the last two decades, more and more light has been shed on the immunologic pathogenesis of autoimmune liver diseases, notably autoimmune hepatitis (AIH). An immunologic dysbalance with proinflammatory immune responses dominating over hepatic tolerance seems to be part of AIH pathogenesis. In detail, an impairment of regulatory T cells (Treg) is suspected. If this holds true and reduced Treg numbers or their function are pathogenic for AIH, this offers the option of cellular or immunomodulatory therapy. However, the exact immunological role of Treg in AIH still needs to be clarified before cellular therapy is promising for patients.

KW - Hepatitis, Autoimmune

KW - Humans

KW - Immunomodulation

KW - Models, Immunological

KW - T-Lymphocytes, Regulatory

U2 - 10.1159/000360493

DO - 10.1159/000360493

M3 - SCORING: Journal article

C2 - 25034282

VL - 32

SP - 502

EP - 506

JO - DIGEST DIS

JF - DIGEST DIS

SN - 0257-2753

IS - 5

ER -